Skip to main content

Table 3 Classification base on the two-year PFS and the AUC value using the clearance of HE4 and CA125

From: Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer

  Two-year PFS Sensitivity Specificity PPV NPV Accuracy P-value AUC
Yes No
  HE4 clearance HE4 non-clearance        
1 cycle 45/59 (76.3%) 14/30 (46.7%) 46.7% 76.3% 50.0% 73.8% 66.3% 0.078 0.615
3 cycle 50/59 (84.7%) 17/30 (56.7%) 56.7% 84.7% 65.4% 79.4% 75.3% 0.001 0.707
6 cycle 51/59 (86.4%) 14/30 (46.7%) 46.7% 86.4% 63.6% 76.1% 73.0% 0.011 0.666
  CA125 clearance CA125 non-clearance        
1 cycle 43/59 (72.9%) 17/30 (56.7%) 56.7% 72.9% 51.5% 76.8% 67.4% 0.023 0.648
3 cycle 56/59 (94.9%) 7/30 (23.3%) 23.3% 94.9% 70.0% 70.9% 70.8% 0.161 0.591
6 cycle 57/59 (96.6%) 7/30 (23.3%) 23.3% 96.9% 77.8% 71.3% 71.9% 0.126 0.600
  HE4 or CA125 clearance Both HE4 and CA125 non-clearance       
3 cycle of HE4 or 1 cycle of CA125 37/59 (62.7%) 25/30 (83.3%) 83.3% 62.7% 53.2% 88.1% 69.7% 0.000 0.730
  Both HE4 and CA125 clearance HE4 or CA125 non-clearance        
3 cycle of HE4 and 1 cycle of CA125 56/59 (94.9) 9/30 (30.0%) 30.0% 94.9% 75.0% 72.7% 73.0% 0.056 0.625